Corline Biomedical AB

Research Corline Biomedical AB (CLBIO) on Bullrun: market cap SEK 371.09M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerCLBIO
ExchangeST
CountrySweden
SectorHealthcare
IndustryBiotechnology
CurrencySEK
Market capSEK 371.09M
Financial periodQ1 2026
RevenueSEK 4.29M
Net income-SEK 2.50M
Free cash flow-SEK 5.97M
Gross margin102.2%

Valuation Snapshot

latest market cap is SEK 371.09M.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	SEK 7.65M	-SEK 14.71M	-SEK 18.67M	81.4%	-0.6	SEK 20.56M	n/a	SEK 93.76M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-07	SEK 371.09M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 SEK.

About Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.

Related stock research

Sweden stocks Sweden Healthcare stocks A-Z stock index

Other Healthcare stocks

Abera Bioscience AB (ABERA.ST) Ascelia Pharma AB (publ) (ACE) AcouSort AB (ACOU) Active Biotech AB (ACTI) AlzeCure Pharma (ALZCUR) Alzinova (ALZ.ST) Annexin Pharmaceuticals (ANNX.ST) Alligator Bioscience AB (ATORX) BioInvent International (BINV.ST) BioArctic AB (publ) (BIOA-B) Biosergen AS (BIOSGN) Biovica International AB (publ) (BIOVIC-B)

Frequently asked questions

What is Corline Biomedical AB's market cap?

Corline Biomedical AB's market capitalization is SEK 371.09M.